Non-invasive diagnosis for idiopathic nephrotic syndrome using blood antibodies and a routine-data score

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This is a prospective observational validation of the SNIT diagnostic score combined with routine blood antibody testing to identify the main differential diagnoses of idiopathic nephrotic syndrome. Consecutive eligible adults hospitalized for a first episode of nephrotic syndrome will have standardized clinical and laboratory data collected and the SNIT score computed automatically in the case report form but hidden from treating clinicians. Patients receive standard medical care and are followed at one month, with final diagnosis obtained from histopathology when a biopsy is performed (within four months). The protocol does not change patient management and aims to compare the non-invasive diagnosis against the reference renal biopsy result.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Patients aged 18 years and older
* Hospitalized for a first episode of nephrotic syndrome (proteinuria greater than 3g/g and albumin level \< 30g/L)
* Negative anti-PLA2r antibodies in the blood
* Requirement for a renal biopsy for diagnostic purposes

Exclusion Criteria:

* Patients with known lupus nephropathy (prior to the current episode)
* Patients with known IgA nephropathy (prior to the current episode)

Where it's running

• Service de Néphrologie et Dialyses, Hôpital Tenon
  Paris, France, France Recruiting

Study contacts

• Principal investigator: Alexandre LAHENS, Dr — Assistance Publique - Hôpitaux de Paris
• Study coordinator: Alexandre LAHENS, Dr
• Email: alexandre.lahens@aphp.fr
• Phone: +33 1 56 01 70 43

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Autoimmune podocytopathy and anti-nephrin antibodies

  This study tests whether children and adults with nephrotic syndrome have anti-nephrin autoantibodies and whether those antibodies relate to relapses and treatment response.

  Recruiting Meyer Children's Hospital IRCCS · Rochester, Minnesota and 13 other locations · NCT07516964

• Treatment with AP1189 for patients with severe proteinuria due to idiopathic membranous nephropathy

  This study is testing if a new drug called AP1189 can help people with severe proteinuria caused by idiopathic membranous nephropathy feel better when added to their current treatment.

  Recruiting Phase 2 SynAct Pharma Aps · Aarhus · NCT04456816

• National cohort of children with idiopathic nephrotic syndrome

  This study is trying to gather information from children with idiopathic nephrotic syndrome to better understand the condition and improve future treatments.

  Recruiting at 45 sites University Hospital, Limoges · Agen and 47 other locations · NCT04207580

• Registry for patients with Focal Segmental Glomerulosclerosis and Minimal Change Disease

  This study is setting up a registry to collect health information and samples from kids and adults with certain kidney diseases to help researchers learn more about them and improve treatments.

  Recruiting at 10 sites University of Cologne · Cologne, North Rhine-Westphalia and 11 other locations · NCT03949972

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.